Gene therapy is expected to gear up in 2020.
Study in human brain tissue shows that NPY can suppress epileptic activity via Y2-receptor activation
Ingeneious #4 2019, News from CombiGene
CombiGene is part of “Sweden to become a world leader in development and implementation of advanced therapies by 2030”,
December 10-12, Gene Therapy for Neurological Disorder, Boston
Nominating committee
CombiGene’s Chairman and CEO increase their shareholdings in the company
Professor Merab Kokaia’s proof-of-concept study has been published in Molecular Therapy: Methods & Clinical Development
The results of the study show that CG01 has clinically relevant anti-seizure effects On February 19th 2018 Professor Merab Kokaia, one of CombiGene’s scientific founders, together with lead scientist Esbjörn Melin presented final data from the preclinical...
CombiGene receives a second payment of EUR 1.21 million from Horizon 2020
Interim Report January-September 2019
Outcome of exercise of warrants in CombiGene
Two significant steps towards the first human studies for CG01
This is an article from Ingenious number three. Read the whole Ingenious here >> CombiGene has recently taken two major steps towards the first studies in humans, so-called clinical studies. The first step has been to identify a suitable CDMO (Contract...
Watch Jan Nilsson, CEO at CombiGene present the company at Stora Aktiedagen in Göteborg november 4 (ONLY IN SWEDISH)
Significant advances in the epilepsy project. Inlicensing of a new gene therapy project. Acquisition of Panion Animal Health.
This is an article from Ingenious number three. Read the whole Ingenious here >> Jan Nilsson, CombiGene’s CEO, is in a characteristically good mood when he sits down at the conference table for this interview with Ingeneious. It’s obvious that a lot is happening...
Ingeneious #3 2019, News from CombiGene
CombiGene attended ESGCT
CombiGene carries out a directed new issue of shares to Lipigon Pharmaceuticals
October 22-25, European Society of Gene and Cell Therapy 27th annual congress, Barcelona
November 4, Stora Aktiedagen, Göteborg
November 11-13, BIO-Europe, Hamburg
CombiGene signs agreement with Cobra Biologics for production of candidate drug CG01
CombiGene expands its operation into metabolic diseases through an inlicensing agreement with Lipigon Pharmaceuticals, thereby strengthening CombiGene’s position as Sweden’s leading gene therapy company
Presentation, Aktiedagen in Lund September 17
Presentation, Aktiedagen in Stockholm, September 10
CombiGene requests initiation of compulsory acquisition proceeding of shares and warrants in Panion
CombiGene chooses the CRO company Northern Biomedical Research as partner for upcoming preclinical biodistribution and safety studies
Interim Report January – June 2019
The Report >> Combigene AB, Medicon Village, SE-223-81 Lund, Visiting adress: Scheelevägen 2, Lund, Sweden "This is an English translation of the Swedish website; if there is any inconsistency or ambiguity between the English version and the Swedish...
CombiGene announces the final result of the offer to the shareholders and the holders of warrants in Panion
CombiGene concludes the offer to the shareholders and the holders of warrants in Panion, ends the acceptance period and resolves on a non-cash consideration shares issue
Intensive science summer
CombiGene announces the result of the offer to the holders of shares and warrants in Panion and extends the acceptance period
Combigene at the fourth Biotech-Hanse Forum
Ingeneious #2 2019, News from CombiGene
CombiGene publishes offer document with respect to the offer to the holders of shares and warrants in Panion Animal Health
The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares or warrants be accepted from or on behalf of holders in Australia, Brazil, Canada, Faroe Islands, Hong Kong, India, Japan, New...
Annual General Meeting of CombiGene 2019
CombiGene’s CEO Jan Nilsson guests AstraZeneca Exchange
Annual Report 2018
CombiGene announces a public offer to the holders of shares and warrants of series TO1 in Panion Animal Health
Notice of annual general meeting in CombiGene AB (publ)
Meet CombiGene at the Cell & Gene Meeting on the Med conference April 23-25, 2019 in Barcelona, Spain!
Internship at CombiGene
CombiGene presents at Stockholm Corporate Finance 11th Life Science Seminar on March 13, 2019
International workshop to discuss mechanisms of epilepsy
Year-end statement January-December 2018
Ingeneious #1 2019, News from CombiGene
CombiGene strengthening its organization and appoints Anna Jönsson as CFO
January 29, Lund Aktiedagen
September 10, Stockholm Aktiedagen
About CombiGene
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations.
The Company has an exclusive collaboration and licensing agreement for the CG01 project with Spark Therapeutics.
The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 info@fnca.se.